Cited 18 times in

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia

DC Field Value Language
dc.contributor.author김수정-
dc.contributor.author이정연-
dc.contributor.author장지은-
dc.contributor.author정준원-
dc.contributor.author김윤덕-
dc.contributor.author김진석-
dc.contributor.author민유홍-
dc.contributor.author박현성-
dc.date.accessioned2017-11-02T08:38:39Z-
dc.date.available2017-11-02T08:38:39Z-
dc.date.issued2017-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154708-
dc.description.abstractPURPOSE: Decitabine, a DNA hypomethylating agent, was recently approved for use in Korea for older adults with acute myeloid leukemia (AML) who are not candidates for standard chemotherapy. This study aimed to evaluate the role of decitabine as a first-line treatment for older adults with AML. MATERIALS AND METHODS: Twenty-four patients with AML who received at least one course of decitabine (20 mg/m²/d intravenously for 5 days every 4 weeks) as a first-line therapy at Severance Hospital were evaluated retrospectively. RESULTS: The median age of the patients was 73.5 years. The longest follow-up duration was 502 days. A total of 113 cycles of treatment were given to 24 patients, and the median number of cycles was four (range, 1-14). Thirteen patients dropped out because of death, no or loss of response, patient refusal, or transfer to another hospital. Twenty-one (87.5%) and 12 (50%) patients completed the second and fourth cycles, respectively, and responses to treatment were evaluated in 17. A complete response (CR) or CR with incomplete blood-count recovery was achieved in six (35.3%) patients, and the estimated median overall survival was 502 days. Ten patients developed grade >2 hematologic or non-hematologic toxicities. In univariate analysis, bone marrow blasts, lactate dehydrogenase, serum ferritin level, and bone marrow iron were significantly associated with response to decitabine. CONCLUSION: Five-day decitabine treatment showed acceptable efficacy in older patients with AML who are unfit for conventional chemotherapy, with a CR rate 35.3% and about a median overall survival of 18 months.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAntimetabolites, Antineoplastic/administration & dosage-
dc.subject.MESHAntimetabolites, Antineoplastic/therapeutic use*-
dc.subject.MESHAzacitidine/analogs & derivatives*-
dc.subject.MESHAzacitidine/therapeutic use-
dc.subject.MESHDNA Methylation-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLeukemia, Myeloid, Acute/drug therapy*-
dc.subject.MESHLeukemia, Myeloid, Acute/mortality-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRemission Induction-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleDecitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia-
dc.typeArticle-
dc.publisher.locationKorea (South)-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHyunsung Park-
dc.contributor.googleauthorHaerim Chung-
dc.contributor.googleauthorJungyeon Lee-
dc.contributor.googleauthorJieun Jang-
dc.contributor.googleauthorYundeok Kim-
dc.contributor.googleauthorSoo Jeong Kim-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJune-Won Cheong-
dc.identifier.doi10.3349/ymj.2017.58.1.35-
dc.contributor.localIdA03114-
dc.contributor.localIdA03477-
dc.contributor.localIdA03729-
dc.contributor.localIdA00790-
dc.contributor.localIdA01017-
dc.contributor.localIdA01407-
dc.contributor.localIdA01740-
dc.contributor.localIdA00633-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid27873493-
dc.subject.keywordAML-
dc.subject.keywordDecitabine-
dc.subject.keywordelderly-
dc.subject.keywordtreatment-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameLee, Jung Yoen-
dc.contributor.alternativeNameJang, Ji Eun-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.alternativeNameKim, Yun Deok-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNamePark, Hyeun Sung-
dc.contributor.affiliatedAuthorLee, Jung Yoen-
dc.contributor.affiliatedAuthorJang, Ji Eun-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.contributor.affiliatedAuthorKim, Yun Deok-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorPark, Hyeun Sung-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.citation.titleYonsei Medical Journal-
dc.citation.volume58-
dc.citation.number1-
dc.citation.startPage35-
dc.citation.endPage42-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.58(1) : 35-42, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid44179-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.